Tetanus Toxin Antibodies Extraction for High Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current tetanus immune globulin (TIG) treatments have limitations, including low specificity for tetanus toxin, high doses required due to low potency, potential for adverse reactions, limited intrathecal administration feasibility, variable neutralization potency between lots, risk of contamination, and immune responses in patients with IgA deficits.
Innovation Solution
Development of antibodies with high binding affinity specifically targeting tetanus toxin, which can be administered in smaller quantities, reducing the risk of adverse reactions and improving treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If polyclonal TIG is used for tetanus treatment, then neutralization of tetanus toxin is achieved, but large amounts of protein need to be injected resulting in adverse reactions
Solution Approach 1:
The patent extracts and isolates the specific anti-tetanus toxin antibodies from the complex polyclonal TIG mixture. By identifying and isolating the specific antibody subpopulations that bind to tetanus toxin with high affinity, the invention eliminates the need to administer large amounts of non-specific proteins that cause adverse reactions, while maintaining effective neutralization potency.
Solution Approach 2:
The patent applies local quality by creating a highly purified antibody preparation with specific binding properties. The isolated anti-tetanus toxin antibodies possess enhanced local quality in terms of binding specificity and affinity, allowing effective treatment with minimal dosage, thereby reducing adverse reactions associated with bulk protein administration.
2Reliability
If polyclonal TIG is administered, then tetanus toxin neutralization is provided, but variable neutralization potency occurs from lot to lot
Solution Approach 1:
The patent extracts the specific anti-tetanus toxin antibody population from variable polyclonal sources and isolates it as a standardized product. This extraction and isolation process ensures that each batch contains the same specific antibody subpopulation with consistent binding characteristics, eliminating lot-to-lot variability in neutralization potency.
Solution Approach 2:
The patent changes the critical parameter of antibody specificity by isolating antibodies with defined binding properties to tetanus toxin. By standardizing the binding affinity and specificity parameters of the antibody preparation, the invention achieves consistent neutralization potency across different batches, overcoming the variability inherent in polyclonal TIG.
3Adaptability or versatility
If polyclonal TIG is used, then broad immune coverage is provided, but contamination with unknown viruses or blood proteins occurs
Solution Approach 1:
The patent extracts only the specific anti-tetanus toxin antibodies from the complex polyclonal mixture, separating them from potential contaminants such as unknown viruses and irrelevant blood proteins. This extraction process maintains the therapeutic immune coverage while eliminating safety risks associated with contamination.
Solution Approach 2:
The patent applies local quality by creating a highly purified antibody preparation with defined specificities. The isolated antibodies possess precise local quality in terms of binding specificity to tetanus toxin, providing targeted immune coverage without the safety risks of contaminants present in bulk polyclonal preparations.
4Reliability
If TIG is administered in large amounts, then adequate neutralization is achieved, but immune responses are elicited in patients with IgA deficit
Solution Approach 1:
The patent extracts and isolates the specific anti-tetanus toxin antibodies from TIG, creating a highly concentrated preparation. This extraction allows administration of minimal doses that achieve adequate neutralization without triggering immune responses in patients with IgA deficit, eliminating the need for large amounts of protein.
Solution Approach 2:
The patent changes the dosage parameter by creating a highly potent, purified antibody preparation. The enhanced specific activity of the isolated antibodies allows reduction of the administered dose to minimal levels, thereby avoiding immune responses in immunocompromised patients while maintaining effective neutralization.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies provide effective neutralization of tetanus toxin with high specificity and potency, potentially reducing the risks associated with current TIG treatments and improving treatment outcomes.
Implementation Method 1
an (isolated) antibody, or an antigen-binding fragment thereof, which (specifically) binds to tetanus toxin
Data Source
AI summary
The present invention relates to antibodies, and antigen binding fragments thereof, that bind to tetanus toxin. The invention also relates to nucleic acids that encode, and to cells that express such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments in the diagnosis, prophylaxis and therapy of infection with Clostridium tetani or tetanus.